ArticleESMO open2017

Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.

Birgit Gaschler-Markefski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.